UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

May 2, 2019

By E-Mail

Aneliya S. Crawford, Esq. Schulte Roth & Zabel LLP 919 Third Avenue New York, NY 10022

Re:

MiMedx Group, Inc.

Soliciting Materials filed pursuant to Rule 14a-12 on April

29, 2019

Filed by Parker H. Petit, David J. Furstenberg, and Shawn P.

George

File No. 001-35887

Dear Ms. Crawford:

We have reviewed your filing and have the following comments.

1. Please revise the answer to the question "Which directors will be elected at the June 17th $\,$

We note that the court order is limited to the three seats designated as ${\it Class\ II}$ directors.

Please ensure that if the disclosure referenced in this comment letter is revised in $% \left(1\right) =\left(1\right) +\left(1\right$

additional filings you also make the revisions to the materials on your website.

2. Please revise in future soliciting materials your reference to the "2019 MiMedx Annual

 $\,$ Meeting." We note that the court's order relates to the 2018 annual meeting.

3. Each statement or assertion of opinion or belief must be clearly characterized as such,

and a reasonable factual basis must exist for each such opinion or belief. Support for

opinions or beliefs should be self-evident, disclosed in the proxy statement or provided to

the staff on a supplemental basis. With a view toward revised disclosure, provide support

for your statement that your nominees "would bring much needed operational, financial

and governance expertise to the Board."

Please direct any questions to me at (202) 551-3619.

Sincerely,

/s/ Daniel F.

Duchovny

Daniel F.

Duchovny

Special Counsel
Office of

Mergers and Acquisitions